Bannerbild German Brest Group

Immunotherapy for breast cancer: what does the future hold

11.10.2016

In dieser Ausgabe, vorgestellt von Fabrice André (Institut Gustave Roussy, Villejuif, Frankreich), tauschen führende Forscher ihre Ansichten über die mögliche Rolle von Immuntherapien bei Brustkrebs und über unser gegenwärtiges Verständnis der Immunantwort auf diese Krankheit aus. Darüber gibt ein Interview von Prof. Gabriel N. Hortobagyi (The University of Texas MD Anderson Cancer Center, USA) einen Einblick in die transatlantischen Bemühungen, den Bereich der Immuntherapien schneller voranzutreiben.

/wAssets/docs/final_bigresearchnews5.pdf

News

  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

    Mehr ...
  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

    Mehr ...
  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

    Mehr ...
  • 13.03.2018 ESMO 2019

    ESMO 2019

    ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd